Livzon MABPharm wins China approval for Lecankitug psoriasis injection

• Livzon MABPharm, a controlling subsidiary of Livzon Pharmaceutical Group, won China NMPA registration for Lecankitug injection (subcutaneous).
• Launch clearance covers adult moderate-to-severe plaque psoriasis patients eligible for systemic therapy or phototherapy.
• Drug is a recombinant IL-17A/F dual-target humanized monoclonal antibody; positioned as the first domestically developed product in China in its class.
• Phase III results versus secukinumab showed faster onset, higher clearance, durable efficacy; safety comparable; dosing less frequent without an induction phase.
• R&D spending reached about RMB 223.31 million; approval number valid until Aug. 24, 2031.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Livzon Pharmaceutical Group Inc. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260827-12302509), on August 27, 2026, and is solely responsible for the information contained therein.